We will particularly emphasize the recent advances in pharmacological targeting of Panx channels using clinically approved drugs (e.g., CBX, PBN) and synthetic peptide inhibitor targeting Panx1 W74 to Y83 (10Panx), and evaluate their therapeutic potential in inflammation and cancer. The gene discussed is PANX1; the disease is cancer.